venBio Partners — 2024 Investments
3 investments dated 2024 · listed companies and verified rows first · show all
Axonis Therapeutics is a biotechnology company developing small-molecule medicines that target KCC2, a mediator of inhibition in the brain, to treat neurological disorders such as epilepsy and pain.
BiotechDeep TechBoston, US
Shane Hegarty(Executive Officer)Shane V. Hegarty(Chief Scientific Officer & Co-Founder)Jeffrey Imbaro(Executive Officer)Joanna Stanicka(Chief Executive Officer, President & Co-Founder)inJeff Imbaro(Chief Operating Officer)Tiasha Shafiq(Chief of Staff)
Co-investorsMRL Ventures FundSofinnova VenturesCivilization Ventures Management, LlcCreative Destruction Lab (CDL)Hatteras Venture PartnersIaso Ventures+7 more
San Francisco, US
Board seatAaron Royston· per SEC Form D · $160.4M raise · filed Jun 2024
Co-investorsSofinnova Ventures
CandidRx develops T-cell engager antibodies to treat autoimmune diseases by redirecting T-cells to eliminate autoreactive B-cells.
BiotechHealthtechSan Diego, US
Ken Song(Chairman, President and CEO)Kenneth Song, M.D.(Executive Officer, Director)Arvind Kush(Executive Officer)Timothy Lu, M.D.(Executive Officer)Bernie Huyghe, Ph.D.(Executive Officer)
BoardJeffrey Tong, Ph.D.(Director)
Co-investorsForesite CapitalOrbiMedSamsara BioCapitalTCG CrossoverThird Rock VenturesVida Ventures
Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.